CW Advisors LLC Has $15.28 Million Stock Position in Bristol Myers Squibb Company $BMY

Key Points

• CW Advisors LLC significantly increased its stake in Bristol Myers Squibb by 49.7%, bringing its total holdings to 250,474 shares valued at approximately $15.28 million.
• Several other hedge funds have also boosted their holdings during the fourth quarter, indicating a strong interest among institutional investors, who collectively own 76.41% of the company.
• Analysts have lowered their ratings on Bristol Myers Squibb from "strong-buy" to "buy," with the current average target price at $56.38 and most analysts rating it as "Hold."

CW Advisors LLC grew its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 49.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 250,474 shares of the biopharmaceutical company's stock after buying an additional 83,127 shares during the quarter. CW Advisors LLC's holdings in Bristol Myers Squibb were worth $15,279,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Commonwealth Equity Services LLC boosted its stake in shares of Bristol Myers Squibb by 1.1% in the first quarter. Commonwealth Equity Services LLC now owns 1,288,407 shares of the biopharmaceutical company's stock valued at $78,580,000 after purchasing an additional 13,959 shares during the period. Polar Asset Management Partners Inc. acquired a new stake in Bristol Myers Squibb in the fourth quarter valued at $16,651,000. Avaii Wealth Management LLC raised its holdings in Bristol Myers Squibb by 590.9% in the first quarter. Avaii Wealth Management LLC now owns 78,597 shares of the biopharmaceutical company's stock valued at $4,794,000 after acquiring an additional 67,221 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Bristol Myers Squibb by 1.4% in the first quarter. Assenagon Asset Management S.A. now owns 65,038 shares of the biopharmaceutical company's stock valued at $3,967,000 after acquiring an additional 869 shares in the last quarter. Finally, Shorepoint Capital Partners LLC raised its holdings in Bristol Myers Squibb by 2.2% in the fourth quarter. Shorepoint Capital Partners LLC now owns 58,426 shares of the biopharmaceutical company's stock valued at $3,305,000 after acquiring an additional 1,248 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Citigroup cut their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a report on Friday, August 1st. Wall Street Zen cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Daiwa America cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Finally, Daiwa Capital Markets cut shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 target price on the stock. in a report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of "Hold" and a consensus price target of $56.38.

Bristol Myers Squibb Trading Up 0.2%

Shares of BMY traded up $0.11 during midday trading on Tuesday, hitting $47.25. The stock had a trading volume of 12,165,506 shares, compared to its average volume of 13,232,382. Bristol Myers Squibb Company has a fifty-two week low of $42.96 and a fifty-two week high of $63.33. The business has a 50-day simple moving average of $47.03 and a two-hundred day simple moving average of $50.94. The firm has a market cap of $96.16 billion, a P/E ratio of 19.05, a price-to-earnings-growth ratio of 2.45 and a beta of 0.36. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. The firm had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm's revenue was up .6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were given a $0.62 dividend. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.2%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 100.00%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.